Changes in the Bone Mineral Density of Femur Neck and Total Hip Over a 52-Week Treatment with Lobeglitazone

Overview

Journal Diabetes Metab J

Specialty Endocrinology

Date 2017 Nov 1

PMID 29086535

Authors

Da Young Lee

Ji A Seo

Affiliations

Soon will be listed here.

References

Farr J, Drake M, Amin S, Melton 3rd L, McCready L, Khosla S . In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res. 2013; 29(4):787-95. PMC: 3961509. DOI: 10.1002/jbmr.2106. View

Kim S, Kim D, Woo J, Jang H, Chung C, Ko K . Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial. PLoS One. 2014; 9(4):e92843. PMC: 3988010. DOI: 10.1371/journal.pone.0092843. View

Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T . Relationships between serum adiponectin levels versus bone mineral density, bone metabolic markers, and vertebral fractures in type 2 diabetes mellitus. Eur J Endocrinol. 2008; 160(2):265-73. DOI: 10.1530/EJE-08-0642. View

Jeyabalan J, Shah M, Viollet B, Chenu C . AMP-activated protein kinase pathway and bone metabolism. J Endocrinol. 2011; 212(3):277-90. DOI: 10.1530/JOE-11-0306. View

Rosen C, Bouxsein M . Mechanisms of disease: is osteoporosis the obesity of bone?. Nat Clin Pract Rheumatol. 2006; 2(1):35-43. DOI: 10.1038/ncprheum0070. View

Wan Y, Chong L, Evans R . PPAR-gamma regulates osteoclastogenesis in mice. Nat Med. 2007; 13(12):1496-503. DOI: 10.1038/nm1672. View

Yki-Jarvinen H . Thiazolidinediones. N Engl J Med. 2004; 351(11):1106-18. DOI: 10.1056/NEJMra041001. View

Lim S, Kim K, Kim S, Kim D, Woo J, Chung C . Effects of Lobeglitazone, a Novel Thiazolidinedione, on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus over 52 Weeks. Diabetes Metab J. 2017; 41(5):377-385. PMC: 5663677. DOI: 10.4093/dmj.2017.41.5.377. View

Kahn S, Zinman B, Lachin J, Haffner S, Herman W, Holman R . Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008; 31(5):845-51. DOI: 10.2337/dc07-2270. View

10.

Schwartz A, Vittinghoff E, Margolis K, Scibora L, Palermo L, Ambrosius W . Intensive glycemic control and thiazolidinedione use: effects on cortical and trabecular bone at the radius and tibia. Calcif Tissue Int. 2013; 92(5):477-86. PMC: 3640571. DOI: 10.1007/s00223-013-9703-0. View

11.

Viegas M, Costa C, Lopes A, Griz L, Medeiro M, Bandeira F . Prevalence of osteoporosis and vertebral fractures in postmenopausal women with type 2 diabetes mellitus and their relationship with duration of the disease and chronic complications. J Diabetes Complications. 2011; 25(4):216-21. DOI: 10.1016/j.jdiacomp.2011.02.004. View

12.

Bruedigam C, van Driel M, Koedam M, van de Peppel J, van der Eerden B, Eijken M . Basic techniques in human mesenchymal stem cell cultures: differentiation into osteogenic and adipogenic lineages, genetic perturbations, and phenotypic analyses. Curr Protoc Stem Cell Biol. 2011; Chapter 1:Unit1H.3. DOI: 10.1002/9780470151808.sc01h03s17. View

13.

Gruntmanis U, Fordan S, Ghayee H, Abdullah S, See R, Ayers C . The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial. Calcif Tissue Int. 2010; 86(5):343-9. DOI: 10.1007/s00223-010-9352-5. View

14.

Rzonca S, Suva L, Gaddy D, Montague D, Lecka-Czernik B . Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology. 2003; 145(1):401-6. PMC: 1855213. DOI: 10.1210/en.2003-0746. View

15.

Zhu Z, Jiang Y, Ding T . Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. Bone. 2014; 68:115-23. DOI: 10.1016/j.bone.2014.08.010. View

16.

Ahmad O, Leong A, Miller J, Morris J, Forgetta V, Mujammami M . A Mendelian Randomization Study of the Effect of Type-2 Diabetes and Glycemic Traits on Bone Mineral Density. J Bone Miner Res. 2016; 32(5):1072-1081. DOI: 10.1002/jbmr.3063. View

17.

Gimble J, ROBINSON C, Wu X, Kelly K, Rodriguez B, Kliewer S . Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol. 1996; 50(5):1087-94. View

18.

Fan Y, Wei F, Lang Y, Liu Y . Diabetes mellitus and risk of hip fractures: a meta-analysis. Osteoporos Int. 2015; 27(1):219-28. DOI: 10.1007/s00198-015-3279-7. View

19.

Kahn S, Haffner S, Heise M, Herman W, Holman R, Jones N . Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355(23):2427-43. DOI: 10.1056/NEJMoa066224. View